(NASDAQ: BOLD) Boundless Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.
Boundless Bio's earnings in 2026 is -$64,012,000.On average, 3 Wall Street analysts forecast BOLD's earnings for 2026 to be -$58,703,450, with the lowest BOLD earnings forecast at -$56,401,354, and the highest BOLD earnings forecast at -$60,430,022. On average, 3 Wall Street analysts forecast BOLD's earnings for 2027 to be -$22,738,886, with the lowest BOLD earnings forecast at -$21,847,165, and the highest BOLD earnings forecast at -$23,407,677.
In 2028, BOLD is forecast to generate -$25,407,224 in earnings, with the lowest earnings forecast at -$34,777,119 and the highest earnings forecast at -$15,047,792.